Japan · Delayed Price · Currency is JPY Sysmex Earnings Call Transcripts
Fiscal Year 2027
-
Sales and profits surged in Q1, led by robust growth in the Americas and favorable FX, while China faced continued declines due to healthcare policies. Upward revisions were made to first half and full year forecasts, with risks from China’s policy changes and one-time expenses factored in.
Fiscal Year 2026
-
New management is prioritizing performance recovery, transparency, and disciplined capital allocation after missing previous targets. Despite profit declines driven by China and one-time impairments, growth continues in Americas, EMEA, and AP, with dividends and buybacks maintained.
-
The midterm management plan prioritizes deepening diagnostics, digital transformation, and global expansion, with ambitious financial targets and a focus on innovation in AI, R&D, and regenerative medicine. Strategic capital allocation and ESG initiatives support sustainable growth.
-
Sales and profits declined year-over-year due to weak China demand, tariffs, and inventory adjustments, prompting a downward revision of full-year forecasts. Americas and EMEA regions showed strong growth, while China and Japan faced significant headwinds.
-
First half results saw declines in revenue and profit due to Japan's ecosystem transition, inventory devaluation, and a challenging Chinese market, while overseas regions excluding China performed well. Full-year forecasts were revised down, but growth is expected in emerging markets and new business areas.